Effect of cisapride on response fluctuations in Parkinson's disease
- PMID: 7885359
- DOI: 10.1002/mds.870100113
Effect of cisapride on response fluctuations in Parkinson's disease
Abstract
Impaired gastric emptying may be the cause for some response fluctuations in Parkinson's disease (PD), especially the "delayed-on" and "no-on" phenomena. Cisapride is a prokinetic drug that enhances gastric emptying by releasing acetylcholine from the myenteric plexus. Tolerability and safety as well as efficacy of cisapride was studied in an open-label trial on 15 fluctuating PD patients. Twelve patients had "delayed-on" and six had "no-no" phenomena. They filled out daily diaries on times of levodopa intake and of turning "on" and "off" for 1 week on levodopa alone and for an additional week of pretreatment with cisapride, 30 min before early morning, early afternoon, and late evening doses of levodopa. Cisapride significantly shortened latency to "on" from 60 +/- 20 to 45 +/- 19 min after the morning dose and from 63 +/- 17 to 47 +/- 22 min after the evening doses. Patients with "no-no" phenomenon had a decreased number of dose failures from 23 before to nine during cisapride treatment. The drug was well tolerated, with no important side effects. Our study supports the role of impaired gastric emptying in some subtypes of motor fluctuations and indicates that they may be improved by prokinetic drugs.
Similar articles
-
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.Isr J Med Sci. 1996 Dec;32(12):1224-7. Isr J Med Sci. 1996. PMID: 9007159 Review.
-
The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.Mov Disord. 1995 Jan;10(1):66-70. doi: 10.1002/mds.870100111. Mov Disord. 1995. PMID: 7885357
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.Arch Neurol. 2005 Feb;62(2):241-8. doi: 10.1001/archneur.62.2.241. Arch Neurol. 2005. PMID: 15710852 Clinical Trial.
-
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2. Fortschr Neurol Psychiatr. 2008. PMID: 18833504 German.
-
Delayed gastric emptying in Parkinson's disease.Mov Disord. 2014 Jan;29(1):23-32. doi: 10.1002/mds.25708. Epub 2013 Oct 21. Mov Disord. 2014. PMID: 24151126 Review.
Cited by
-
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.Mov Disord. 2018 Feb;33(2):329-332. doi: 10.1002/mds.27259. Epub 2017 Dec 26. Mov Disord. 2018. PMID: 29278279 Free PMC article. Clinical Trial.
-
Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test.J Neurol. 2011 Mar;258(3):421-6. doi: 10.1007/s00415-010-5769-z. Epub 2010 Oct 12. J Neurol. 2011. PMID: 20938781
-
Constipation in neurological diseases.J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):13-9. doi: 10.1136/jnnp.74.1.13. J Neurol Neurosurg Psychiatry. 2003. PMID: 12486259 Free PMC article. Review.
-
New perspectives in the diagnosis and management of enteric neuropathies.Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):206-18. doi: 10.1038/nrgastro.2013.18. Epub 2013 Feb 12. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23399525 Review.
-
Pharmacokinetic optimisation in the treatment of Parkinson's disease.Clin Pharmacokinet. 1996 Jun;30(6):463-81. doi: 10.2165/00003088-199630060-00004. Clin Pharmacokinet. 1996. PMID: 8792058 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical